

In the Claims

1-62 (Canceled).

63 (currently amended). An isolated polypeptide comprising an amino acid sequence ~~having that has~~ at least 95% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide ~~has the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

64 (previously presented). The isolated polypeptide according to claim 63, wherein said polypeptide comprises SEQ ID NO: 100.

65 (previously presented). The isolated polypeptide according to claim 63, wherein said polypeptide consists of SEQ ID NO: 100.

66 (currently amended). The isolated polypeptide according to claim 63, wherein said polypeptide has at least 96% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide ~~has the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

67 (currently amended). The isolated polypeptide according to claim 63, wherein said polypeptide has at least 97% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide ~~has the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

68 (currently amended). The isolated polypeptide according to claim 63, wherein said polypeptide has at least 98% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide ~~has the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

69 (currently amended). The isolated polypeptide according to claim 63, wherein said polypeptide has at least 99% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide has ~~the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

70 (currently amended). A composition comprising a carrier and a polypeptide comprising an amino acid sequence ~~having that has~~ at least 95% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide has ~~the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

71 (previously presented). The composition according to claim 70, wherein said polypeptide comprises SEQ ID NO: 100.

72 (previously presented). The composition according to claim 70, wherein said polypeptide consists of SEQ ID NO: 100.

73 (currently amended). The composition according to claim 70, wherein said polypeptide has at least 96% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide has ~~the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

74 (currently amended). The composition according to claim 70, wherein said polypeptide has at least 97% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide has ~~the activity of a germinal-center kinase activity or~~ activates the MAP kinase pathway.

75 (currently amended). The composition according to claim 70, wherein said polypeptide has at least 98% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID

NO: 100 and wherein said polypeptide has ~~the activity of a germinal-center kinase~~ activity or activates the MAP kinase pathway.

76 (currently amended). The composition according to claim 70, wherein said polypeptide has at least 99% identity ~~over its full length to the amino acid sequence of~~ to SEQ ID NO: 100 and wherein said polypeptide has ~~the activity of a germinal-center kinase~~ activity or activates the MAP kinase pathway.

77 (previously presented). The composition according to claim 70, wherein said carrier is a pharmaceutical carrier.

78 (previously presented). The composition according to claim 70, wherein said carrier is an adjuvant.